Exhibit 31.2

                                  CERTIFICATION

I, MECHAEL KANOVSKY, PH.D., CERTIFY THE FOLLOWING:

1.       I have reviewed this quarterly report on Form 10-QSB of Amazon Biotech,
         Inc.;

2.       Based on my knowledge, this quarterly report does not contain any
         untrue statement of a material fact or omit to state a material fact
         necessary to make the statements made, in light of the circumstances
         under which such statements were made, not misleading with respect to
         the period covered by this quarterly report;

3.       Based on my knowledge, the financial statements, and other financial
         information included in this quarterly report, fairly present in all
         material respects the financial condition, results of operations and
         cash flows of Amazon Biotech, Inc. as of, and for, the periods
         presented in this quarterly report;

4.       Amazon Biotech, Inc.'s other certifying officer and I are responsible
         for establishing and maintaining disclosure controls and procedures (as
         defined in Exchange Act Rules 13a-14 and 15d-14) for Amazon Biotech,
         Inc. and we have done the following:

a.       designed such disclosure controls and procedures to ensure that
         material information relating to Amazon Biotech, Inc. is made known to
         us by others within the Company, particularly during the period in
         which this quarterly report is being prepared;

b.       evaluated the effectiveness of Amazon Biotech, Inc.'s disclosure
         controls and procedures as of a date within 90 days prior to the filing
         date of this quarterly report (the "Evaluation Date"); and

c.       presented in this quarterly report our conclusions about the
         effectiveness of the disclosure controls and procedures based on our
         evaluation as of the Evaluation Date;

5.       Amazon Biotech, Inc.'s other certifying officer and I have disclosed,
         based on our most recent evaluation, to Amazon Biotech, Inc.'s auditors
         and the audit committee of Amazon Biotech Inc.'s board of directors:

a.       all significant deficiencies in the design or operation of internal
         controls which could adversely affect Amazon Biotech, Inc.'s ability to
         record, process, summarize and report financial data and have
         identified for Amazon Biotech, Inc.'s auditors any material weaknesses
         in internal controls; and

b.       any fraud, whether or not material, that involves management or other
         employees who have a significant role in Amazon Biotech, Inc.'s
         internal controls; and

6.       Amazon Biotech, Inc.'s other certifying officer and I have indicated in
         this quarterly report whether or not there were significant changes in
         internal controls or in other factors that could significantly affect
         internal controls subsequent to the date of our most recent evaluation,
         including any corrective actions with regard to significant
         deficiencies and material weaknesses.


March 17, 2005                                 /s/ Mechael Kanovsky, Ph.D.
                                               ---------------------------------
                                                   Mechael Kanovsky, Ph.D.
                                                   President
                                                   (Principal Financial Officer)